PMSF Research Roundup: March 2022
Do you wonder how a research publication affects your loved one or the field of Phelan-McDermid research? The Research Roundup is…
Use this for any post that you want on the home page
Enrollment is currently open for Phase II of the Phelan-McDermid syndrome (PMS) Natural History Study
The Natural History Study is funded by NIH and the goal is to help medical professionals study PMS and how it progresses over time. This information is essential for developing clinical guidelines, identifying research priorities, and assessing the effectiveness of the clinical intervention.
A pilot study of Growth Hormone in children with Phelan-McDermid syndrome
Results from a study testing the safety and feasibility of using growth hormone (GH) as a treatment in children with Phelan-McDermid syndrome has just been published.
PMSF Research Roundup: February 2022
Do you wonder how a research publication affects your loved one or the field of Phelan-McDermid research? The Research Roundup is…
Phelan-McDermid Syndrome Foundation Offers Travel Assistance for Clinical Research Studies
This Phelan-McDermid Syndrome Foundation Travel Assistance Program is designed to assist patients and families with the cost of travel expenses associated with the clinical research study regarding a Phelan-McDermid syndrome diagnosis.
PMSF Scientific Advisory Committee Revisits Definition of Phelan-McDermid Syndrome
The Phelan-McDermid Syndrome Foundation Scientific Advisory Committee has proposed a new classification system for Phelan-McDermid syndrome in an important new publication.
Phelan Lucky 2022 Is Here!
Phelan Lucky 2022 is an online campaign that takes place for a strict 22-day period—from Jan. 2, 2022, through Jan. 24, 2022! It’s also the only time of year to get your hands on the coveted “Phelan Lucky” T-shirt.
PMSF Research Roundup: January 2022
Do you wonder how a research publication affects your loved one or the field of Phelan-McDermid research?The Research Roundup is a…
Jaguar Gene Therapy Will Target SHANK3 for Gene Therapy
JAG201 is designed to address mutation or deletion of the SHANK3 gene, a leading autism candidate gene, by delivering SHANK3 gene replacement therapy.
PMSF Research Roundup: December 2021
Do you wonder how a research publication affects your loved one or the field of Phelan-McDermid research?The Research Roundup is a…